Balance Sheet Details |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance Sheet Details [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance Sheet Details | Note 4 — Balance Sheet Details
Inventories
Inventories, which primarily relate to Proclarix product as of June 30, 2026 and December 31, 2025, consisted of the following:
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consisted of the following as of June 30, 2026, and December 31, 2025:
Goodwill
Goodwill consisted of the following as of June 30, 2026 and December 31, 2025:
Impairments for three and six months ended June 30, 2026 and 2025
During the three and six months ended June 30, 2026 and 2025, the Company’s stock price and market capitalization declined, and the Company determined that this was an indicator of a potential impairment of its goodwill. Accordingly, as of June 30, 2026 and 2025, the Company performed quantitative analysis to identify and measure the amount of impairment losses to be recognized. The Company recognized goodwill impairment losses of approximately $0.5 million and $0.6 million for the three months ended June 30, 2026 and 2025, respectively. The Company recognized goodwill impairment losses of approximately $8.6 million and $11.5 million for the six months ended June 30, 2026 and 2025, respectively.
The fair value of the reporting unit is estimated using a market approach. Beginning in the second quarter of 2024, the Company elected to use a market capitalization reconciliation methodology as its sole valuation technique in estimating the fair value of the reporting unit. Under this approach, the fair value of the reporting unit is determined based on the Company's market capitalization, calculated using the quoted market price of its common stock and outstanding shares, with consideration given to whether adjustments are necessary to reconcile market capitalization to the fair value of the reporting unit.
Accrued Expenses
Accrued expenses consisted of the following as of June 30, 2026 and December 31, 2025:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||